Charles Schwab Investment Management Inc. Increases Stock Holdings in RxSight, Inc. (NASDAQ:RXST)

Charles Schwab Investment Management Inc. lifted its stake in RxSight, Inc. (NASDAQ:RXST) by 28.1% during the third quarter, HoldingsChannel reports. The institutional investor owned 285,329 shares of the company’s stock after acquiring an additional 62,507 shares during the period. Charles Schwab Investment Management Inc.’s holdings in RxSight were worth $14,104,000 as of its most recent SEC filing.

A number of other large investors have also recently made changes to their positions in RXST. California State Teachers Retirement System grew its position in shares of RxSight by 6.8% during the first quarter. California State Teachers Retirement System now owns 27,052 shares of the company’s stock worth $1,395,000 after acquiring an additional 1,733 shares during the last quarter. CWM LLC grew its holdings in RxSight by 727.5% during the second quarter. CWM LLC now owns 422 shares of the company’s stock worth $25,000 after acquiring an additional 371 shares during the period. SG Americas Securities LLC purchased a new position in RxSight in the second quarter worth $3,754,000. M&G Plc lifted its holdings in RxSight by 12.4% in the second quarter. M&G Plc now owns 159,005 shares of the company’s stock valued at $9,540,000 after acquiring an additional 17,577 shares during the period. Finally, Raymond James & Associates purchased a new position in shares of RxSight in the 2nd quarter valued at about $3,549,000. 78.78% of the stock is owned by institutional investors and hedge funds.

RxSight Stock Up 2.1 %

Shares of RXST opened at $43.15 on Monday. The firm has a market cap of $1.74 billion, a PE ratio of -51.99 and a beta of 1.11. The company’s fifty day moving average is $48.01 and its two-hundred day moving average is $51.53. RxSight, Inc. has a fifty-two week low of $33.09 and a fifty-two week high of $66.54.

Insider Buying and Selling at RxSight

In other news, insider Ilya Goldshleger sold 3,105 shares of the firm’s stock in a transaction on Friday, November 29th. The shares were sold at an average price of $46.08, for a total value of $143,078.40. Following the transaction, the insider now owns 42,246 shares of the company’s stock, valued at approximately $1,946,695.68. This trade represents a 6.85 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Shweta Maniar sold 3,782 shares of the company’s stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $45.88, for a total transaction of $173,518.16. Following the sale, the director now directly owns 10,902 shares of the company’s stock, valued at approximately $500,183.76. This trade represents a 25.76 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 65,807 shares of company stock valued at $3,202,275. Company insiders own 9.36% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently weighed in on RXST. UBS Group assumed coverage on RxSight in a report on Friday. They issued a “buy” rating and a $52.00 price target on the stock. Jefferies Financial Group assumed coverage on RxSight in a report on Tuesday, October 29th. They issued a “buy” rating and a $72.00 price target for the company. Finally, Needham & Company LLC reiterated a “buy” rating and set a $66.00 price target on shares of RxSight in a report on Friday, September 13th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, RxSight presently has a consensus rating of “Buy” and a consensus price target of $63.63.

RxSight Profile

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.